On May 30th 2019, Martin Musiol (RA/QA Manager, IPD Inc) led “The Keys to Quality: Introduction to Good Manufacturing Practices, Quality Management Systems, and Working in Regulated Environments.”
Recapping 2019 OBIO Queen's Park Health Science Industry Showcase
Reviewing 'Game Planning to Build Strong IP'
Reviewing 'Going Virtual for Product Development, Manufacturing & Clinical Trials'
Reviewing the 2019 Niagara Investment Summit, Day 2
Picking up where we left off last week, the second day of the 2019 Niagara Investment Summit (February 20th-22nd, 2019) continued on the first day’s theme: bringing together CEOs and senior executives from Canada’s most innovative health science companies with investors and strategics in beautiful Niagara-on-the-Lake.
Reviewing the 2019 Niagara Investment Summit, Day 1
The OBIO 2019 Niagara Investment Summit, held in historic Niagara-on-the-Lake from February 20th through 22nd, brought together CEOs and senior executives representing Canadian health science companies from Halifax to Vancouver, global investors and venture capitalists, and health science industry leaders for two panels of company presentations, one-on-one meetings, panel discussions and keynote speakers.
Reviewing OBIO’s 'How BDC & EDC Can Help Your Business'
Reviewing OBIO’s Cross-Border Investing Panel
OBIO’s recent Cross Border Investing panel on January 31, 2019, hosted by Osler Hoskin & Harcourt LLP and moderated by Gail Garland (CEO, OBIO), featured David Young (CEO, Kisoji Biotechnology), Mike Cooke (CEO, AmacaThera) and Chad Bayne (Partner, Osler) answering questions on their experiences raising money for Canadian companies from international investors.
Reviewing OBIO’s C-Suite Pub Night
OBIO 2018 Annual General Meeting: Recap and Photo Gallery
On November 28th, OBIO held our 2018 Annual General Meeting at the offices of Norton Rose Fulbright. The exciting event featured Nik Nanos, our keynote speaker whose presentation Global Disruption: How to Make Decisions in an Age When Truth and Data are No Longer Enough to Persuade scanned recent global political experiences and explained the outsized influence of the margins, both on electoral outcomes as well as the impact for your company.
Reviewing ‘Talking to Doctors and Patients: Using Primary Market Research Data to Seal the Deal with Investors’
Reviewing ‘Doing Deals with Strategics & Investors: Getting on Their Radar and Staying There’
Recapping the OBIO Canadian Health Investment Showcase in New York City: Photo Gallery
OBIO Hosts CEO2CEO Networking Event
Reviewing OBIO's Workshop: "No Project Was Ever Completed On Time and Within Budget." - Cheops Law
On September 18th, OBIO organized a workshop with two industry experts and provided the CFO perspective on budgeting for start-up and growing health science companies.
John Jordan (CFO, RNA Diagnostics) and Jim Cooke (Partner, Stoneybridge Partners) addressed 3 main areas – how to build a robust budget, how to present a budget to the board and to investors and how to manage a budget.
OBIO Hosts Chief Investment Officer, Biomedical Development Board of Taiwan
OBIO Hosts Delegation From National Cheng Kung University
OBIO Hosts Dr. Jonathan Shieh, Taipei Economic and Cultural Office and Government of Ontario officials
Last week, OBIO hosted a day of meetings with Dr. Jonathan Shieh, Executive Director, Science and Technology Division of the Taipei Economic and Cultural Office which brought Dr. Shieh together with officials from the Ontario government, Ministry of Economic Development, Job Creation and Trade, as well as high-potential Ontario health science companies.
Recapping 'How Do VCs Value Health Science Companies? From Valuation to Deal Structure'
On June 25th, OBIO organized a workshop with two industry leaders and provided a VC perspective on how they valuate start-up companies and on how this is translated into a deal structure, featuring presentations by Richard Meadows (General Partner, BioInnovation Capital Fund & OBIO Board Director) and Andy Haigh (COO, Adapsyn Bioscience).